Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines

Yoshikazu Sugimoto, Satomi Tsukahara, Tomoko Oh-hara, Leroy F. Liu, Leroy-Fong Liu

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

In a previous study, we established camptothecin (CPT)-resistant cell lines, A549/CPT and HT-29/CPT, from human lung cancer A549 and human colon cancer HT-29. A549/CPT was shown to express similar amounts of DNA topoisomerase I (topo I) as the parental line, and HT-29/CPT was shown to express lower amounts of topo I than its parental line. DNA topoisomerases I and II are known to be functionally related. In the present study, the possible alterations in topo II expression were examined in these human CPT-resistant lines. In A549/CPT and HT-29/ CPT, the cellular contents of topo II and its mRNA were elevated over that seen in each parental line. Nuclear extracts from A549/CPT and HT-29/CPT showed higher topo II activity than those from the corresponding parental lines when the same amounts of nuclear protein were used. Topo II was partially purified from HT-29 and HT-29/CPT by hydroxylapatite column chromatography, and the enzyme activities were compared. HT-29/CPT showed higher topo II activity in the hydroxylapatite column-eluted fractions than HT-29. These results indicate the possible activation of topo II expression in the CPT-resistant cell lines.

Original languageEnglish
Pages (from-to)7962-7965
Number of pages4
JournalCancer Research
Volume50
Issue number24
Publication statusPublished - Dec 15 1990
Externally publishedYes

Fingerprint

Camptothecin
Type II DNA Topoisomerase
Tumor Cell Line
Type I DNA Topoisomerase
Durapatite
Nuclear Proteins
Colonic Neoplasms
Chromatography
Lung Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sugimoto, Y., Tsukahara, S., Oh-hara, T., Liu, L. F., & Liu, L-F. (1990). Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Research, 50(24), 7962-7965.

Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. / Sugimoto, Yoshikazu; Tsukahara, Satomi; Oh-hara, Tomoko; Liu, Leroy F.; Liu, Leroy-Fong.

In: Cancer Research, Vol. 50, No. 24, 15.12.1990, p. 7962-7965.

Research output: Contribution to journalArticle

Sugimoto, Y, Tsukahara, S, Oh-hara, T, Liu, LF & Liu, L-F 1990, 'Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines', Cancer Research, vol. 50, no. 24, pp. 7962-7965.
Sugimoto, Yoshikazu ; Tsukahara, Satomi ; Oh-hara, Tomoko ; Liu, Leroy F. ; Liu, Leroy-Fong. / Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. In: Cancer Research. 1990 ; Vol. 50, No. 24. pp. 7962-7965.
@article{7af8c5019b394430936a7e8f0201bf5a,
title = "Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines",
abstract = "In a previous study, we established camptothecin (CPT)-resistant cell lines, A549/CPT and HT-29/CPT, from human lung cancer A549 and human colon cancer HT-29. A549/CPT was shown to express similar amounts of DNA topoisomerase I (topo I) as the parental line, and HT-29/CPT was shown to express lower amounts of topo I than its parental line. DNA topoisomerases I and II are known to be functionally related. In the present study, the possible alterations in topo II expression were examined in these human CPT-resistant lines. In A549/CPT and HT-29/ CPT, the cellular contents of topo II and its mRNA were elevated over that seen in each parental line. Nuclear extracts from A549/CPT and HT-29/CPT showed higher topo II activity than those from the corresponding parental lines when the same amounts of nuclear protein were used. Topo II was partially purified from HT-29 and HT-29/CPT by hydroxylapatite column chromatography, and the enzyme activities were compared. HT-29/CPT showed higher topo II activity in the hydroxylapatite column-eluted fractions than HT-29. These results indicate the possible activation of topo II expression in the CPT-resistant cell lines.",
author = "Yoshikazu Sugimoto and Satomi Tsukahara and Tomoko Oh-hara and Liu, {Leroy F.} and Leroy-Fong Liu",
year = "1990",
month = "12",
day = "15",
language = "English",
volume = "50",
pages = "7962--7965",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines

AU - Sugimoto, Yoshikazu

AU - Tsukahara, Satomi

AU - Oh-hara, Tomoko

AU - Liu, Leroy F.

AU - Liu, Leroy-Fong

PY - 1990/12/15

Y1 - 1990/12/15

N2 - In a previous study, we established camptothecin (CPT)-resistant cell lines, A549/CPT and HT-29/CPT, from human lung cancer A549 and human colon cancer HT-29. A549/CPT was shown to express similar amounts of DNA topoisomerase I (topo I) as the parental line, and HT-29/CPT was shown to express lower amounts of topo I than its parental line. DNA topoisomerases I and II are known to be functionally related. In the present study, the possible alterations in topo II expression were examined in these human CPT-resistant lines. In A549/CPT and HT-29/ CPT, the cellular contents of topo II and its mRNA were elevated over that seen in each parental line. Nuclear extracts from A549/CPT and HT-29/CPT showed higher topo II activity than those from the corresponding parental lines when the same amounts of nuclear protein were used. Topo II was partially purified from HT-29 and HT-29/CPT by hydroxylapatite column chromatography, and the enzyme activities were compared. HT-29/CPT showed higher topo II activity in the hydroxylapatite column-eluted fractions than HT-29. These results indicate the possible activation of topo II expression in the CPT-resistant cell lines.

AB - In a previous study, we established camptothecin (CPT)-resistant cell lines, A549/CPT and HT-29/CPT, from human lung cancer A549 and human colon cancer HT-29. A549/CPT was shown to express similar amounts of DNA topoisomerase I (topo I) as the parental line, and HT-29/CPT was shown to express lower amounts of topo I than its parental line. DNA topoisomerases I and II are known to be functionally related. In the present study, the possible alterations in topo II expression were examined in these human CPT-resistant lines. In A549/CPT and HT-29/ CPT, the cellular contents of topo II and its mRNA were elevated over that seen in each parental line. Nuclear extracts from A549/CPT and HT-29/CPT showed higher topo II activity than those from the corresponding parental lines when the same amounts of nuclear protein were used. Topo II was partially purified from HT-29 and HT-29/CPT by hydroxylapatite column chromatography, and the enzyme activities were compared. HT-29/CPT showed higher topo II activity in the hydroxylapatite column-eluted fractions than HT-29. These results indicate the possible activation of topo II expression in the CPT-resistant cell lines.

UR - http://www.scopus.com/inward/record.url?scp=0025686125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025686125&partnerID=8YFLogxK

M3 - Article

C2 - 2174738

AN - SCOPUS:0025686125

VL - 50

SP - 7962

EP - 7965

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 24

ER -